USA: +1 617 939 9497 | UK: +44 2039 962936 | EU: +34 607 939 266 info@sofpromed.com
Select Page

Do Clinical Trial Recruitment Ads Require IRB Approval in the US?

Patricio Ledesma

Sofpromed's CEO and Founder. Global Director of Clinical Operations. 15+ years of experience in managing clinical trials.

16 November, 2026

Patricio Ledesma presenting IRB approval requirements for clinical trial recruitment ads in the United States

By Patricio Ledesma, Founder and CEO, Sofpromed

Table of Contents

I'm Patricio Ledesma.

Today I want to answer a very common question.

Do clinical trial recruitment advertisements need IRB approval in the United States?

The short answer is:

Yes.

In most cases.

Recruitment materials are considered part of the informed consent and subject recruitment process.

The FDA and IRBs pay close attention to them.

Let's see what the regulations say.

What Is a Recruitment Advertisement?

A recruitment advertisement is any material used to recruit study participants.

Examples include:

  • Facebook ads
  • Google ads
  • YouTube ads
  • Newspaper ads
  • Radio ads
  • Website banners
  • Flyers
  • Posters
  • Patient brochures

The format does not matter.

If the purpose is recruitment, it is usually considered advertising.

Does FDA Require IRB Review?

Yes.

According to FDA guidance:

The IRB should review recruitment procedures and recruitment materials before they are used.

This includes advertisements intended to recruit subjects into a clinical trial.

Official Reference

FDA Information Sheet Guidance for IRBs and Clinical Investigators:

"Advertising for Study Subjects."

The FDA states that recruitment advertisements should be reviewed as part of the IRB's responsibilities for protecting human subjects.

Why Does the IRB Review Ads?

The goal is simple.

Protect potential study participants.

The IRB wants to ensure that advertisements:

  • Are accurate
  • Are not misleading
  • Do not overpromise benefits
  • Do not minimize risks
  • Do not create undue influence

Patient protection always comes first.

What Information Can Be Included?

According to FDA guidance, recruitment materials may include factual information.

Examples:

Table 1: Acceptable content for recruitment materials

Information Type Generally Acceptable
Study title Yes
Study purpose Yes
Disease being studied Yes
Basic eligibility criteria Yes
Study location Yes
Contact information Yes
Time commitment Yes
Compensation information Yes

Source: FDA IRB Information Sheet Guidance.

What Should NOT Be Included?

This is where sponsors often make mistakes.

Table 2: Common problems in recruitment ads

Statement FDA Concern
"New breakthrough treatment" Implies effectiveness
"Best treatment available" Promotional claim
"Guaranteed improvement" Misleading
"Safe and effective" Not yet established
"Free treatment" May overemphasize benefit

These claims may improperly influence patients.

The FDA specifically warns against implying that the investigational product is known to be safe or effective.

Can Payment Be Mentioned?

Yes.

Compensation can be described.

However:

The payment should not be presented as an incentive that overwhelms a person's ability to make a voluntary decision.

The IRB will often review:

  • Amounts
  • Payment schedule
  • Wording

For example:

Better Wording

"Participants may receive up to $500 for time and travel."

Riskier Wording

"Earn $500 fast by joining this study."

The first is factual.

The second may create undue influence.

What About Social Media Advertising?

This is especially important today.

Many studies recruit through:

  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • TikTok

The same principles apply.

The platform does not change the regulatory requirements.

The IRB generally reviews:

  • Text
  • Images
  • Videos
  • Landing pages
  • Digital banners

Everything seen by potential participants.

What Does OHRP Say?

The Office for Human Research Protections (OHRP) also considers recruitment materials part of the subject selection process.

OHRP guidance states that IRBs should review recruitment methods and materials to ensure ethical enrollment practices.

This is particularly important in vulnerable populations.

Examples include:

  • Children
  • Cognitively impaired subjects
  • Economically disadvantaged populations

FDA Examples of Acceptable Recruitment Language

Let's look at examples.

Acceptable

"Researchers are conducting a study of an investigational treatment for migraine."

Acceptable

"Participants must be between 18 and 65 years old."

Acceptable

"Study-related procedures will be provided at no cost."

These statements are factual.

FDA Examples of Problematic Language

Not Recommended

"Try a promising new cure."

Not Recommended

"Be among the first to benefit from a breakthrough treatment."

Not Recommended

"Safe new therapy available now."

These statements imply efficacy or safety.

Those claims have not yet been established.

Practical Sponsor Checklist

Before launching recruitment advertisements, I recommend confirming the following:

Table 3: Sponsor compliance checklist

Requirement Complete?
IRB approval obtained □
Final advertisement version controlled □
Contact information verified □
Compensation wording reviewed □
No efficacy claims included □
No safety claims included □
Social media content reviewed □
Screenshots archived □

Key Regulations and Guidance Documents

FDA Regulations

21 CFR 50 Protection of Human Subjects.

21 CFR 56 Institutional Review Boards.

FDA Guidance

Recruiting Study Subjects - Information Sheet Guidance for IRBs and Clinical Investigators

OHRP Guidance

Institutional Review Board Guidebook

These documents form the foundation for recruitment advertising review in U.S. clinical trials.

Key Takeaways

Let's summarize.

Do recruitment advertisements require IRB approval?

Generally:

Yes.

Before use.

Recruitment materials should be:

  • Accurate
  • Balanced
  • Non-promotional
  • Non-coercive

They must not:

  • Promise benefits
  • Exaggerate effectiveness
  • Minimize risks
  • Create inappropriate pressure to participate

Good recruitment starts with ethical communication.

And ethical communication protects patients.

Figure 1: Key aspects regarding clinical trial recruitment ads in the United States

Infographic summarizing IRB review of recruitment ads, acceptable content, compensation wording and prelaunch checks

Conclusion

If your company is planning patient recruitment activities for a clinical trial, make sure your advertisements are reviewed by your IRB before launch.

A compliant recruitment strategy can prevent regulatory findings and protect patient trust.

Patricio Ledesma

Patricio Ledesma (B.Eng Concordia University, Montreal, Canada and Master’s Degree in Clinical Trials, University of Seville, Spain) is the Head of Clinical Operations and Founder at Sofpromed CRO. Patricio is a professional consultant providing comprehensive, one-stop expert advice and guidance to biotechnology and pharmaceutical companies worldwide in the field of clinical trials and drug development. He is personally and enthusiastically devoted to helping biotech Chief Executive, Operations, Scientific, Medical, and Regulatory Officers in the planning and execution of phase I-IV clinical trials across North America, Europe, Asia-Pacific, Latin America, and Middle East regions. You can contact Patricio at: +34 607 939 266  pledesma@sofpromed.com 

You may also be interested...

Patricio Ledesma

Patricio Ledesma (B.Eng Concordia University, Montreal, Canada and Master’s Degree in Clinical Trials, University of Seville, Spain) is the Head of Clinical Operations and Founder at Sofpromed CRO. Patricio is a professional consultant providing comprehensive, one-stop expert advice and guidance to biotechnology and pharmaceutical companies worldwide in the field of clinical trials and drug development. He is personally and enthusiastically devoted to helping biotech Chief Executive, Operations, Scientific, Medical, and Regulatory Officers in the planning and execution of phase I-IV clinical trials across North America, Europe, Asia-Pacific, Latin America, and Middle East regions. You can contact Patricio at: +34 607 939 266 pledesma@sofpromed.com